Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, discusses the causes of renal insufficiency in patients with multiple myeloma, commenting on the optimal management of these patients. According to Prof. Vij, it is important to treat patients with therapies that allow them to recover renal function early in order to ensure better long-term outcomes. In addition, Prof. Vij notes that whilst patients can be treated with existing anti-myeloma therapies, they may require dose reductions. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

James Bond shares his experience being diagnosed with, treated for, and living with multiple myeloma, and his wife Kathleen shares her strategies for supporting a loved one with multiple myeloma.

Meral Beksac, MD, Ankara University, Ankara, Turkey, gives an overview of her talk on response monitoring in multiple myeloma at EBMT 2021. Dr Beksac outlines the most significant prognostic and response monitoring tools, including urine and serum free light chain measurement, next generation sequencing, PET-CT and measurable residual disease (MRD). Dr Beksac also outlines the latest clinical trials employing MRD for myeloma response assessment. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, shares some insights into the use of the first-in-class peptide-drug conjugate melflufen for treating patients with relapsed/refractory multiple myeloma (R/R MM). Dr Cerchione explains that many patients with MM relapse after multiple prior lines of antibody-based or cellular therapy. However, recent data from the HORIZON (NCT02963493) and OCEAN (NCT03151811) clinical trials have demonstrated the efficacy of melflufen in this patient group. Dr Cerchione further notes that melflufen is currently best used as a monotherapy but may be beneficial in combination therapies with further research. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Mary DeRome, Senior Director of Medical Communications and Education at the Multiple Myeloma Research Foundation, gets answers to frequently asked questions about multiple myeloma diagnosis, prognosis, and initial treatment from the University of Chicago’s Dr. Benjamin Derman (Assistant Professor of Medicine) and Sarah Major (physician assistant), as well as myeloma patient Julia Grosch.

Dr. Derman, Ms. Major, and Ms. Grosch provide insights on a range of topics relating to newly diagnosed multiple myeloma, such as...
00:35 Precursor conditions
08:37 MM diagnosis and prognosis
21:54 Initial treatment and response
52:00 Side effects and other issues

This session is supported by Adaptive, Bristol Myers Squibb, Genentech, GSK, Janssen, Karyopharm, and Takeda.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841-6673.

At the Myeloma 2015 meeting, Dr Bruno Paiva (University of Navarra, Spain) discusses the utility of flow cytometry as a therapeutic tool to identify precursor cells and detect the presence or absence of minimal residue disease (MRD) in multiple myeloma.

Speaker: Bruno Paiva

In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his opinion on the possibility of achieving cure in multiple myeloma. Prof. Mohty explains that cure needs to be clearly defined for different patient subgroups, and further compares approaches to achieving cure in elderly patients versus younger patients, highlighting the importance of sustained measurable residual disease (MRD) negativity in this process. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.